Publication:
Clinical applications of noncoding RNAs in lung cancer patients

Simple item page
dc.contributor.authorKumar, Santosh
dc.contributor.authorVishvakarma, Naveen Kumar
dc.contributor.authorKumar, Ajay
dc.date.accessioned2025-01-27T10:20:19Z
dc.date.available2025-01-27T10:20:19Z
dc.date.issued2022
dc.description.abstractLung cancer is the most diagnosed and the foremost cause of cancer-associated deaths worldwide. In recent few decades, noncoding RNAs (ncRNAs) are identified as a key genomic product, which tightly control the expression of various target genes involved in the regulation of various crucial cellular and pathological processes. Interestingly, the role of aberrant expression of ncRNAs has been reported in the development and progression of various cancers, including lung cancer. They are considered one of the promising biomarkers for the prognosis and diagnosis of lung cancer. Furthermore, ncRNAs are not only identified as potential predictive markers for chemo- and radioresistance in lung cancer but also have a great therapeutic value in designing novel therapeutic regimens against lung cancer. The present chapter provides detailed information regarding the role of ncRNAs in the pathogenesis of lung cancer along with their clinical applications. � 2022 Elsevier Inc. All rights reserved.
dc.identifier.doihttps://doi.org/10.1016/B978-0-12-824550-7.00009-6
dc.identifier.isbn978-012824550-7; 978-012824551-4
dc.identifier.urihttps://dl.bhu.ac.in/ir/handle/123456789/15082
dc.publisherElsevier
dc.subjectChemoresistance
dc.subjectDiagnosis
dc.subjectLncRNA
dc.subjectLung cancer
dc.subjectMiRNA
dc.subjectPrognosis
dc.subjectRadioresistance
dc.titleClinical applications of noncoding RNAs in lung cancer patients
dc.typeBook chapter
dspace.entity.typePublication
journal.titleClinical Applications of Noncoding RNAs in Cancer

Files

Collections

2022